HOPE-B Trial Update: Gene Therapy Candidate AMT-061 Meeting Goals

HOPE-B Trial Update: Gene Therapy Candidate AMT-061 Meeting Goals

314008

HOPE-B Trial Update: Gene Therapy Candidate AMT-061 Meeting Goals

After 18 months, the investigational gene therapy AMT-061 (etranacogene dezaparvovec) continued to prevent bleeds in men with moderate-to-severe hemophilia B, according to top-line data from the Phase 3 HOPE-B clinical trial. The trial has met its pre-specified primary goal, with control of all bleeds by 18 months not being inferior to the bleed control seen during the trial’s six-month lead-in period. The study also has reached a secondary goal, with AMT-061 being statistically superior at…

You must be logged in to read/download the full post.